Tau positron emission tomography imaging in tauopathies: The added hurdle of off‐target binding

Abstract

Abstract Ligands targeting tau for use with positron emission tomography have rapidly been developed during the past several years, enabling the in vivo study of tau pathology in patients with Alzheimer's disease and related non‐Alzheimer's disease tauopathies. Several candidate compounds have been developed, showing good in vitro characteristics with respect to their ability to bind tau deposits; off‐target binding, however, has also been observed. In this short commentary, we briefly summarize the available in vivo and in vitro evidence pertaining to their off‐target binding and discuss the different approaches that are needed for the future development of tau positron emission tomography tracers.

Keywords

• Tau PET
• Off‐target
• AV‐1451
• THK5351
• THK5117
• THK5317